Exhibit 32.1
CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q (the “Report”) of 4D Molecular Therapeutics, Inc. (the “Company”) for the period ended June 30, 2024, David Kirn, as Chief Executive Officer of the Company, and Uneek Mehra, as Chief Financial Officer of the Company, each hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:
Dated: August 8, 2024
By: | /s/ David Kirn |
| David Kirn |
| Chief Executive Officer |
| (Principal Executive Officer) |
Dated: August 8, 2024
By: | /s/ Uneek Mehra |
| Uneek Mehra |
| Chief Financial and Business Officer |
| (Principal Financial and Accounting Officer) |